Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Shutter Indian Research Subsidiary
January 11, 2017
- Plavix AG Now Has All Same Indications as Originator
January 11, 2017
- Daiichi Sankyo Gets Japan Rights to Kite’s CAR T-Cell Therapy
January 11, 2017
- Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
- Teva Takeda Recalls Ciprofloxacin Generic
January 11, 2017
- Janssen, Fukushima Medical Univ. to Engage in Joint Research for ADHD Biomarkers
January 11, 2017
- Pharma Leaders Urge Govt to Lend Ear to Industry Opinions for Pricing Revamp
January 10, 2017
- Otsuka Files Schizophrenia Med Brexpiprazole in Japan
January 10, 2017
- Takeda, US Biotech Strike Deal on Celiac Disease Treatment
January 10, 2017
- Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status
January 10, 2017
- Takeda to Buy US Oncology Firm Ariad
January 10, 2017
- Eisai Expands Deal with Arena, Gets All Global Rights to Belviq
January 6, 2017
- Kyowa Kirin’s KRN23 Filed in Europe for X-Linked Hypophosphatemia
January 6, 2017
- SSP Now under Sanofi Group in Japan after BI Biz Swap
January 6, 2017
- ASKA Eyes 33% Rise in Women’s Health Sales by FY2020
January 5, 2017
- ASKA Ties Up with TesoRx on Oral Testosterone Therapy
January 5, 2017
- Takeda Makes Foray into Consumer Diagnostic Biz with Ovulation, Pregnancy Tests
December 28, 2016
- Opdivo Filed for Gastric Cancer in Japan: Ono
December 28, 2016
- AZ Returns Meropenem Rights in Southeast Asia, HK to Sumitomo Dainippon
December 27, 2016
- SBI, Kubota to Form JV for Ophthalmic Drugs, Devices
December 27, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…